Duloxetine for the Treatment of Dysthymia

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborator: Eli Lilly and Company
• Treatments: Duloxetine Hydrochloride

Criteria

Inclusion Criteria::

• Sign an informed consent form

• 18 years of age or older

• Females not pregnant or breastfeeding or planning pregnancy and using an acceptable form of contraception

• Meet DSM-IV criteria for dysthymia

• A screening IDS-C score of 17 or greater

• No history of serious or unstable medical disorder

• Not taking any significant concurrent medications

• Not currently receiving psychotherapy Exclusion Criteria:- Suffering from DSM-IV defined

• delirium, dementia, amnestic, or other cognitive disorders

• mental disorders due to a general medical condition

• factitious or somatoform disorders

• mental retardation or developmental disabilities

• substance or alcohol abuse within the last 3 months

• depressive disorders with current suicidal risk

• psychotic disorders including delusional disorder, somatic type

• dissociative disorder

• personality disorders sufficiently severe to interfere with study participation

• History of DSM-IV defined bipolar I or II disorder

• History of non-response of dysthymia to adequate antidepressant medication

• History of major depression refractory to two adequate trials of antidepressants